Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1892-1897

  Borin, Marie T ^a   Cox, Steven R ^a   Herman, Beth D ^a   Carel, Barbara J ^a   Anderson, Roger D ^a   Freimuth, William W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; DRUG METABOLITE; FLUCONAZOLE; HYDROCORTISONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STEADY STATE;

EID: 0030809545     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1892     Document Type: Article

References (38)

1. Baciewicz, A. M., and F. A. Baciewicz. 1993. Ketoconazole and fluconazole drug interactions. Arch. Intern Med. 153:1970-1976.
2. Batts, D. H., W. W. Freimuth, S. R. Cox, B. G. Peel, C. K. Hanover, L. K. Wathen, and B. A. Staton. 1993. Open-label escalating multiple-dose study of the safety, tolerance, and pharmacokinetics of oral U-90152S (delavirdine, DLV) in HIV-1 infected males and females with CD4 counts of 200-500 cells/mm3, who are maintained on a stable dose of AZT, abstr. 564, p. 158. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology, Washington, D.C.
3. Blum, R. A., J. H. Wilton, D. M. Hilligoss, M. J. Gardner, E. B. Henry, N. J. Harrison, and J. J. Schentag. 1991. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 49:420-425.
4. Borin, M. T., M. R. Driver, C. P. Wajszczuk, and R. D. Anderson. 1994. The effect of fluconazole on the pharmacokinetics of atevirdine mesylate in HIV+ patients. Clin. Pharmacol. Ther. 55:193.
5. Borin, M. T., J. H. Chambers, B. J. Carel, S. Gagnon, and W. W. Freimuth. 1997. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther., 61:544-553.
6. Borin, M. T., J. H. Chambers, B. J. Carel, W. W. Freimuth, S. Aksentijevich, and A. A. Piergies. 1997. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antivir. Res., 35:53-63.
7. Bruzzese, V. L., J. G. Gillum, D. S. Israel, G. L. Johnson, L. G. Kaplowitz, and R. E. Polk. 1995. Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 39:1050-1053.
8. Cantilena, L. R., S. Sorrels, T. Wiley, and D. Wortham. 1995. Fluconazole alters terfenadine pharmacokinetics and electrocardiographic pharmacodynamics. Clin. Pharmacol. Ther. 57:185.
9. Cheng, C.-L., D. E. Smith, P. L. Carver, S. R. Cox, P. B. Watkins, D. S. Blake, C. A. Kauffman, K. Meyer, G. L. Amidon, and P. L. Stetson. 1997. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin. Pharmacol. Ther. 61:531-543.
10. Chong, K. T., P. J. Pagano, and R. R. Hinshaw. 1994. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits HIV-1 replication in vitro. Antimicrob. Agents Chemother. 38:288-293.
11. Collignon, P., B. Hurley, and D. Mitchell. 1989. Interaction of fluconazole with cyclosporin. Lancet i:1262.
12. Cox, S. R., D. H. Batts, P. Ward, W. W. Freimuth, B. A. Staton, B. G. Peel, C. K. Hanover, K. M. Donaldson, and J. D. Harry. 1993. Escalating single and multiple dose safety, tolerance and pharmacokinetics (PK) of delavirdine mesylate (DLV, U-90152S) in normal volunteers, ahstr. 562, p. 158. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology, Washington, D.C.
13. Cox, S. R. 1996. Personal communication.
14. Debruyne, D., and J. Ryckelynck. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27.
15. DeMuria, D., A. Forrest, J. Rich, J. M. Scavone, L. G. Cohen, and P. H. Kazanjian. 1993. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob. Agents Chemother. 37:2187-2192.
16. Doecke, C. J., M. E. Veronese, S. M. Pond, J. O. Miners, D. J. Birkett, L. N. Sansom, and M. E. McManus. 1991. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31:125-130.
17. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. I. Mayers, and J. Lane. 1993. U-90152S, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1127-1131.
18. Ehninger, G., K. Jaschonek, U. Schuler, and H. U. Kruger. 1989. Interaction of fluconazole with cyclosporin. Lancet ii:104-105.
19. Ged, C., J. M. Rouillon, L. Pichard, J. Combalbert, N. Bressot, P. Bories, H. Michel, P. Beaune, and P. Maurel. 1989. The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28:373-387.
20. Honig, P. K., D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena. 1993. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53:630-636.
21. Jurima-Romet, M., K. Crawford, T. Cyr, and T. Inaba. 1994. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 22:849-857.
22. Konishi, H., K. Morita, and A. Yamaji. 1994. Effect of fluconazole on theophylline disposition in humans. Eur. J. Clin. Pharmacol. 46:309-312.
23. Kowalsky, S. F., and D. M. Dixon. 1991. Fluconazole: a new antifungal agent. Clin. Pharm. 10:179-191.
24. LaDelfa, I., Y. F. Xia, and T. F. Blaschke. 1990. Dose-dependent inhibition of cyclosporine metabolism in mice by fluconazole. Can. J. Physiol. Pharmacol. 68:89-93.
25. Lazar, J. D., and K. D. Wilner. 1990. Drug interactions with fluconazole. Rev. Infect. Dis. 12:8327-8333.
26. Lim, J., F. Aweeka, S. Tsunoda, T. Prueksaritanont, S. Tomlanovich, and L. Z. Benet. 1994. The effect of fluconazole on the pharmacokinetic disposition of intravenously administered cyclosporine and its metabolites in renal transplant recipients. Clin. Pharmacol. Ther. 55:149.
27. Lopez-Gil, J. A. 1993. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann. Pharmacother. 27:427-430.
28. Morita, K., H. Konishbi, and H. Shimakawa. 1992. Fluconazole, a potent inhibitor of cytochrome P-450 dependent drug-metabolism in mice and humans in vivo: comparative study with ketoconazole. Chem. Pharm. Bull. 40:1247-1251.
29. Morrow, J. D. 1991. Fluconazole: a new triazole antifungal agent. Am. J. Med. Sci. 302:129-132.
30. Narang, P. K., C. B. Trapnell, J. R. Schoenfelder, J. P. Lavelle, and J. R. Bianchine. 1994. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330:1316-1317.
31. Perry, C. M., R. Whittington, and D. McTavish. 1995. Fluconazole: an update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs 49:984-1006.
32. Romero, D. L., M. Busso, C.-K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Novel non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
33. Staton, B. A., M. G. Johnson, J. M. Friis, and W. J. Adams. 1995. Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J. Chromatogr. B Biomed. Appl. 668:99-106.
34. Tett, S., S. Moore, and J. Ray. 1995. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob. Agents Chemother. 39:1835-1841.
35. Veronese, M. E., M. E. McManus, P. Laupattarakasem, J. O. Miners, and D. J. Birkett. 1990. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Drug Metab. Dispos. 18:356-361.
36. Voorman, R. L. 1995. Personal communication.
37. Voorman, R. L., S. M. Maio, and X. Wang. 1995. Mechanism-based inactivation of rat and human cytochrome P450 3A by delavirdine. In Abstracts of the Ninth International Conference on Cytochrome P450, Zurich, Switzerland.
38. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.